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Purpose: To describe 1-year clinical results of intravitreal ranibizumab treatment in patients with 
choroidal neovascularization secondary to exudative age-related macular degeneration (AMD) 
and to evaluate whether early treatment is a predictive value for prognosis of the disease.
Materials and methods: Clinical records were retrospectively reviewed of 104 eyes that 
underwent intravitreal ranibizumab therapy for exudative AMD. Patients were divided into two 
groups according to their symptom duration: group 1, ,1 month; and group 2, 1–3 months. 
After three monthly injections, patients were examined monthly, and subsequent injections 
were performed as needed.
Results: There were 43 female (48.9%) and 45 males (51.1%). The follow-up time was 13.7±1.9 
(12–19) months. The mean logarithm of minimum angle of resolution best-corrected visual  acuity 
(BCVA) improved significantly, from 0.45±0.639 at baseline to 0.08±0.267 at 12 months in 
group 1, and from 1.06±0.687 at baseline to 0.75±0.563 at 12 months in group 2. The increase 
in BCVA was statistically significant in group 1 (P=0.009). The mean central retinal thickness 
(CRT) decreased significantly, from 355.13±119.93 µm at baseline to 250.85±45.48 µm at 
12 months in group 1, and from 371.88±91.047 µm at baseline to 268.61±53.51 µm at 12 months 
in group 2. The decrease in CRT was statistically significant in group 1 (P=0.001).
Conclusion: Intravitreal ranibizumab therapy was effective in significantly increasing mean 
BVCA and reducing CRT. Shorter duration of AMD, as measured by the subjective duration 
of visual symptoms, is associated with better visual outcome after treatment.
Keywords: age-related macular degeneration (AMD), optical coherence tomography (OCT), 
ranibizumab, visual acuity
Introduction
Age-related macular degeneration (AMD) is the leading cause of vision loss in the 
world. Choroidal neovascularization (CNV) plays the main role in visual deteriora-
tion in exudative AMD.1–3 CNV originating from choriocapillaris and invading the 
retina is the result of ongoing inflammation that is mainly stimulated by vascular 
endothelial growth factor (VEGF).4–6 Inhibition of VEGF by anti-VEGF agents can 
improve prognosis in exudative AMD by suppressing angiogenesis and decreasing 
vascular permeability.7,8 Major clinical trials have reported the superior efficacy of 
ranibizumab, which is a US Food and Drug Administration-approved anti-VEGF 
agent (Lucentis; Genentech, San Francisco, CA, USA).9,10 Thus, intravitreal injection 
of ranibizumab has become the standard therapy for AMD worldwide.11 However, 
there are still controversial issues on the efficiency of ranibizumab and visual outcome. 
The delay between the onset of symptoms and the timing of the therapy is reported 
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to be in negative correlation with the outcome.6,12 In AMD, 
CNV was found to enlarge at an average of 10 (1–24) µm 
per day.13 Although the predictive value of this rate is small, 
it is important to stress the timing of treatment initiation. The 
purpose of the current study was to report the 1-year clinical 
results of intravitreal ranibizumab treatment in patients with 
exudative AMD, and to evaluate whether early treatment is 
of predictive value for prognosis of the disease.
Materials and methods
Medical reports of patients who underwent intravitreal 
injections of ranibizumab for new-onset exudative AMD 
between March 2010 and January 2013 at Başkent University 
School of Medicine Department of Ophthalmology were 
reviewed retrospectively. This study was approved by the 
Başkent University Institutional Review Board and Ethics 
Committee. The following parameters were achieved from 
patient’s chart at baseline and after 12 months: all patients 
underwent full ophthalmic examination, which included 
best-corrected visual acuity (BCVA), intraocular pressure, 
slit-lamp biomicroscopy, and dilated fundus examination. 
Central retinal thickness (CRT) measurements were done 
by spectral domain optical coherence tomography (OCT) 
(RTVue; Optovue, Fremont, CA, USA). Fluorescein angiog-
raphy was performed at initial diagnosis. In the charts, 
BCVA was assessed using Snellen visual acuity and it was 
converted to a logarithm of the minimum angle of resolution 
(logMAR) value for statistical analysis. BCVA assessments 
were done by the same clinic staff who recorded the data. 
All patients were treated with three consecutive monthly 
intravitreal injections of ranibizumab and followed up for at 
least 12 months. After three monthly injections, patients were 
examined monthly, and subsequent injections were performed 
as needed (pro re nata) for any recurrence.  Recurrence was 
defined as decrease of at least one line in visual acuity, or 
presence of new macular hemorrhage on CNV and the pres-
ence of intraretinal and/or subretinal fluid, and an increase 
of 50 µm or over in central retinal thickness in OCT scans. 
Written informed consent was obtained from all patients 
before administration of the intravitreal ranibizumab. After 
the eye had been prepared using 5% povidone–iodine, 0.5 mg 
of ranibizumab was injected via the pars plana. The dura-
tion of the disease was quantified according to the patients’ 
history from the very beginning of visual symptoms (visual 
distortion, changes in vision acuity, or central blurring) to 
initial presentation. Patients were divided into two groups: 
group 1 consisted of patients with visual symptoms for less 
than 1 month, and patients who had visual symptoms for 
1–3 months were placed in group 2. Included patients had 
symptoms for a maximum of 3 months, underwent at least 
three injections, and completed 1-year follow-up. The exclu-
sion criteria were any previous treatment for CNV and CNV 
that was not associated with AMD.
statistical analysis
Statistical analysis was performed using the statistical 
package SPSS version 17.0 (IBM, Armonk, NY, USA). 
For each continuous variable, normality was checked by 
Kolmogorov–Smirnov and Shapiro–Wilk tests and by 
 histograms. Comparisons between groups were applied using 
the Mann–Whitney U test for data not normally distributed. 
Pre- and postinjection changes were analyzed with Wilcoxon 
and repeated-measures analyses (Greenhouse–Geisser). 
 Values of P,0.05 were considered statistically significant.
Results
A total of 104 eyes of 88 patients were involved in the study; 
there were 40 eyes in group 1 (16.2±4.8 days, 7–30 days), 
and 64 eyes in group 2 (53.1±14.2 days, 35–90 days). 
The mean age of the patients was 68.5±9.6 (50–87) years. 
There were 43 female (48.9%) and 45 males (51.1%). The 
follow-up time was 13.7±1.9 (12–19) months. At baseline, 
the mean logMAR BCVA was 0.45±0.639 (0–3) in group 1 
and 1.06±0.687(0–3) in group 2. The mean logMAR BCVA 
values per group after treatment are shown in Table 1. The 
increase in VA was statistically significant for the first, 
third, sixth, ninth, and twelfth months in group 1 and group 
2  compared to baseline (P,0.0001). The mean logMAR 
Table 1 Mean logarithm of minimum angle of resolution best-corrected visual acuity changes over 12 months of treatment with 
intravitreal ranibizumab for exudative age-related macular degeneration
Group Before therapy After therapy
1 month 3 months 6 months 12 months
1 0.45±0.639 0.15±0.362 0.12±0.335 0.2±0.405 0.08±0.267
2 1.06±0.687 0.78±0.453 0.73±0.479 0.69±0.531 0.75±0.563
P* ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001
Note: *P,0.05 was considered statistically significant.
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BCVA improved significantly, from 0.45±0.639 at baseline to 
0.08±0.267 at 12 months in group 1, and from 1.06±0.687 at 
baseline to 0.75±0.563 at 12 months in group 2. The increase 
in BCVA was statistically significant in group 1 (P=0.009). 
At the final follow-up, BCVA was increased in 56.7% of 
the eyes and decreased in 14.5% of the eyes. In 30 (28.8%) 
eyes, visual acuity remained unchanged at 12 months. 
Baseline mean CRT was 355.13±119.93 (200–775) µm 
in group 1 and 371.88±91.047 (234–714) µm in group 2. 
Mean CRT values per group after treatment are shown in 
Table 2. The decrease in CRT was statistically significant 
for the third month between group 1 and group 2 compared 
to baseline (P=0.046). Mean CRT decreased significantly, 
from 355.13±119.93 µm at baseline to 250.85±45.48 µm 
at 12 months in group 1, and from 371.88±91.047 µm at 
baseline to 268.61±53.51 µm at 12 months in group 2. The 
decrease in CRT was statistically significant in group 1 
(P=0.001). A graphical representation of CRT and BCVA 
over time is shown in Figures 1 and 2. The mean number of 
intravitreal ranibizumab injections applied in the 12-month 
period was 4.32 (range 3–9). The mean number of injections 
was 4.57±1.4 (3–9) in group 1 and 4.17±0.9 (3–6) in group 2. 
There was no significant difference between the two groups 
(P=0.092). No inflammation, infection, ocular toxicity signs, 
or systemic side effects were seen.
Discussion
Several clinical key trials, such as MARINA (Minimally 
 Classic/Occult Trial of the Anti-VEGF Antibody  Ranibizumab 
in the Treatment of Neovascular AMD), ANCHOR (Anti-
VEGF Antibody for the Treatment of Predominantly 
Classic Choroidal Neovascularization in AMD), and 
SAILOR (A Study to Evaluate Ranibizumab in Subjects 
with Choroidal Neovascularization [CNV] Secondary to 
Age-Related Macular Degeneration) have demonstrated 
the efficacy and safety of ranibizumab injections for the 
entire spectrum of CNV subtypes.9–11,14,15 In the PrONTO 
(Prospective OCT Study with Lucentis for Neovascular 
AMD) trial, after the three consecutive monthly intravitreal 
injections, further injections were administered according 
to changes in BCVA, OCT, and ophthalmoscopic macula 
findings.16,17 These reinjection criteria were also used in our 
study. Results of the PrONTO study (mean improvement in 
BCVA of 9.2 letters, mean 5.6 injections) were comparable 
with MARINA or ANCHOR, which assumes stabilization 
and improvement of visual acuity with a decreased number of 
injections.16 In our study, a mean of 4.32 (3–9) injections were 
performed during a 12-month period to achieve recovery of 
BCVA and CRT parameters. In the PrONTO study, the mean 
CRT was 394 µm at baseline and 216 µm at 12 months.16 In 
our study, mean CRT declined from 365.43±102.87 µm to 
261.78±51.09 µm at 12 months. Reduction in CRT was sta-
tistically significant in group 1 (P=0.001). A shorter duration 
of visual symptoms (group 1) was correlated with a higher 
initial and final BCVA (P=0.009). Rauch et al reported that 
CNV with shorter disease duration yielded better visual 
outcome when compared with eyes with longer duration 
after two injections per eye at the 6-month  follow-up.6 
They particularly reported favorable results in patients with 
a duration of less than 1 month. Oliver-Fernandez et al 
reported that 44% of patients lost vision and 15% lost more 
than three lines of visual acuity in 28 days.12 Muether et al 
also stressed the negative effect of delay in treatment on 
visual outcome in two recent reports.18,19 Analysis of our 
results demonstrates that intravitreal ranibizumab treatment 
for exudative AMD clearly preserved and improved mean 
visual acuity in our patients. Shorter duration of AMD, as 
measured by the subjective duration of visual symptoms, was 
associated with a better visual outcome after treatment. The 
retrospective design and the small sample size are perhaps 
limitations of our study. The duration of the disease was 
based on the subjective history given by the patients. This 
is also considered as a shortcoming. However, there is no 
way to assess objective duration. Our study was designed to 
retrospectively analyze 1-year clinical results of intravitreal 
ranibizumab injections in patients with exudative AMD 
and to stress that early diagnosis and prompt therapy are 
associated with favorable outcomes. Currently, intravitreal 
Table 2 Central retinal thickness (CrT) changes over 12 months of treatment with intravitreal ranibizumab for exudative age-related 
macular degeneration
Group Before therapy After therapy
1 month 3 months 6 months 12 months
1 355.13±119.93 246.88±57.73 254.3±69.67 256.35±44.78 250.85±45.48
2 371.88±91.047 260.78±62.28 271.88±61.15 279.83±67.62 268.61±53.51
P* 0.204 0.233 0.046 0.074 0.079
Note: *P,0.05 was considered statistically significant.
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Figure 1 Change in BCVA (logMAr) before and after ranibizumab therapy.
Note: error bars: 95% CI.
Abbreviations: BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; CI, confidence interval.
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Figure 2 Change in CrT before and after ranibizumab therapy.
Note: error bars: 95% CI. 
Abbreviations: CRT, central retinal thickness; CI, confidence interval.
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Intravitreal ranibizumab for exudative AMD
ranibizumab is the gold-standard therapy for exudative 
AMD. Better baseline visual acuity and early treatment is 
essential. Patients must be informed about self-awareness of 
visual symptoms. Prospective randomized studies with larger 
sample sizes would reveal more predictive results.
Disclosure
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